RANCHO LOS AMIGOS NATIONAL REHABILITATION CENTER

Infection Prevention and Control

SUBJECT:	REPORTING OF INFECTIONS	Policy No.:	IC104
		Last Revision:	07/2016
		Reviewed:	07/2022
		Page:	1 of 13

A. Medical or nursing staff will report the following types of infections or problems to the Infection Preventionist(s) at extension 57447 for evaluation and consultation:

- 1. All surgical wound infections (inpatient and outpatients)
- 2. All orders for isolation precautions
- 3. All isolation cases being transferred to or from other units or facilities.
- 4. Isolation being discontinued on an inpatient
- 5. All Central Line infections
- 6. All referrals to Employee Health Services for infectious problems
- 7. Any clustering of possible infections identified in an area (i.e., diarrhea, respiratory, or wounds)
- 8. Any suspected potential infectious problem
- 9. New procedures or devices related to direct patient care
- 10. Any change in current procedures related to direct patient care.
- 11. Report all TB or TB suspects to Infection Prevention and Control regardless of isolation status. In addition, notify Infection Prevention and Control before discharge the TB patient or TB suspect. See Administrative Policy B839.

The list of reportable diseases (see Attachment A) on the following page must be reported to the Los Angeles County Department of Public Health on a Confidential Morbidity Report (CMR) Form (see Attachment B). If the disease has not been reported, the form may be obtained from the Infection Prevention and Control Office. Generally, the primary physician is responsible for reporting diseases once the diagnosis has been made. For the reporting of tuberculosis, a special GOTCH bill reporting form is required, see *Tuberculosis Plan, policy IC 300 A.*

B. Report of infection that was identified after admission and the presence of infection was unknown to the referring organization at the time of transfer:

The Infection Preventionist(s) will notify the referring organization for the following conditions:

- 1. After receiving admission from another healthcare organization, Rancho determined that the patient had a communicable disease, e.g., TB that was not known during treatment by the referring organization.
- 2. Rancho determines that there is a surgical site infection within the first 30 days following surgery at the referring organization.

The following table is the most current list of reportable diseases and conditions from LA County Department of Public Health Acute communicable Disease Program revised February 11, 2022.

Please Post Revised February 11, 2022 v1



REPORTABLE DISEASES AND CONDITIONS

Title 17, California Code of Regulations (CCR), § 2500

It is the duty of every health care provider, knowing of or in attendance on a case or suspected case of any of the diseases or conditions listed below, to report to the local health officer for the jurisdiction where the patient resides. "Health care provider" encounterpasses physicians (surgeons, cateopaths, oriental medicine practitioners), veterinarians, podiatrists, physician assistants, registered nurses (nurse practitioners, nurse midwives, school nurses), infection control professionals, medical occuminarisoromers, dentities, and chiropractors, as well as any other person with knowledge of a case or suspected case.

Note: This list is specific to Los Angeles County and differs from state and federal reporting requirements ★

- Report immediately by telephone for both confirmed and suspected cases.
 - Monkeypox is an unusual disease which requires immediate report by telephone or Weblink.
- Report by telephone within 1 working day from identification COVID-19 Online Reporting** OR COVID-19 Death Online reporting***
- Report by electronic transmission (including FAX or email), telephone or mail within 1 working day from identification
- D Report by electronic transmission (including FAX or email), telephone or mail within 7 calendar days from identification
- Mandated by and reportable to the Los Angeles County Department of Public Health
- ± If enrolled, report electronically via the National Healthcare Safety Network (www.cdc.gov/nhsn/index.html). If not enrolled, use the LAC DPH CRE Case Report Form (publichealth.lacounty.gov/acd/Diseases/EpiForms/CRERepSNF.pdf)
- For TB reporting questions: contact the TB Control Program (213) 745-0800 or visit www.publichealth.lacounty.gov/tb/healthpro.htm
- For HIV/STD reporting questions: contact the Division of HIV and STD Programs. HIV (213) 351-8516, STDs (213) 368-7441 www.publichealth.lacounty.gov/dhsp/ReportCase.htm

For laboratory reporting: www.publichealth.lacounty.gov/lab/index.htm For veterinary reporting: www.publichealth.lacounty.gov/vet/index.htm

REPORTABLE COMMUNICABLE DISEASES 0 Anaplasmosis Giardiasis Poliovirus Infection Anthrax, human or animal Gonococcal Infection Psittacosis Babesiosis Haemophilus influenzae, invasive disease Q Fever Botulism: infant, foodborne, or wound only, all serotypes, less than 5 years of age 2 Rabies, human or animal (2) Brucellosis, animal; except infections due to Hantavirus Infection Relapsing Fever Hemolytic Uremic Syndrome Respiratory Syncytial Virus, only deaths in a Brucella canis Brucellosis, human Hepatitis A, acute infection patient less than 5 years of age න Rickettsial Diseases (non-Rocky Mountain Campylobacteriosis Hepatitis B, specify acute, chronic, or Spotted Fever), including Typhus and perinatal Candida auris * Carbapenem-Resistant Enterobacteriaceae Hepatitis C, specify acute, chronic, or Typhus-like Illnesses (CRE), including Klebsiella sp., E. coli, and perinatal Hepatitis D (Delta), specify acute or chronic Rocky Mountain Spotted Fever Enterobacter sp., in acute care hospitals or skilled nursing facilities *± Ô Rubella (German Measles) Hepatitis E, acute infection Rubella Syndrome, Congenital Chagas Disease * Human Immunodeficiency Virus (HIV), Salmonellosis, other than Typhoid Fever Chancroid . acute infection • (§2641.30-2643.20) Scombroid Fish Poisoning Chickenpox (Varicella), only hospitalizations, deaths, and outbreaks (≥3 Human Immunodeficiency Virus (HIV) 2 Shiga Toxin, detected in feces infection, any stage • ' cases, or one case in a high-risk setting) Human Immunodeficiency Virus (HIV) Smallpox (Variola) Chikungunya Virus Infection infection, progression to stage 3 (AIDS) ■* Streptococcus pneumoniae: Invasive cases Influenza-associated deaths in laboratory Cholera 0 only (sterile body site infections) * Ciguatera Fish Poisoning confirmed cases, all ages ★ Streptococcus pyogenes (Group A Streptococcus): Invasive cases only Coccidioidomycosis Influenza, due to novel strains, human COVID-19 hospitalizations (COVID-19 including necrotizing fasciitis and STSS * Legionellosis Online Reporting**) COVID-19, deaths (COVID-19 Death Leprosy (Hansen's Disease) Syphilis, all stages including congenital . Tetanus Leptospirosis Trichinosis Creutzfeldt-Jakob Disease (CJD) and other Transmissible Spongiform Lyme Disease Malaria Tuberculosis ■ Tularemia, animal Encephalopathies (TSE) Measles (Rubeola) Tularemia, human Cryptosporidiosis Meningitis, specify etiology: viral, bacterial, Typhoid Fever, cases and carriers න Cyclosporiasis fungal, or parasitic Vibrio Infection Cysticercosis or Taeniasis Meningococcal Infection Viral Hemorrhagic Fevers, human or animal (e.g., Crimean-Congo, Ebola, Lassa and 0 Dengue Virus Infection Middle East Respiratory Syndrome (MERS) Mumps Diphtheria Marburg viruses) Myelitis, acute flaccid * Domoic Acid (Amnesic Shellfish) Poisoning West Nile Virus (WNV) Infection Yellow Fever Ehrlichiosis Nontuberculosis mycobacteria Encephalitis, specify etiology: viral, (extrapulmonary) * Yersiniosis bacterial, fungal or parasitic Escherichia coll, shiga toxin producing (STEC) including E. coll O157 Novel virus infection with pandemic Zika Virus Infection potential OCCURRENCE OF ANY Paralytic Shellfish Poisoning UNUSUAL DISEASE Flavivirus infection of undetermined species Paratyphoid Fever Foodborne Disease Pertussis (Whooping Cough) OUTBREAKS OF ANY DISEASE, including Foodborne Outbreak: 2 or more suspected Plaque, human or animal diseases not listed above. Specify if in an * Use of FAX for HIV reporting is highly discouraged in order institution and/or the open community. cases from separate households with same to protect patient confidentiality

REPORTABLE NON-COMMUNICABLE DISEASES OR CONDITIONS

Disorders Characterized by Lapses of Consciousness (CCR § 2806, § 2810) @ Cancer, including benign and borderline brain tumors (CCR §2593)

To report a case or outbreak of any disease, contact the Communicable Disease Reporting System Tel: (888) 397-3993 or (213) 240-7821 • Fax: (888) 397-3778 or (213) 482-5508 • Email: ACDC-MorbidityUnit@ph.lacounty.gov * COVID-19 Cases Only: COVID19@ph.lacounty.gov • Fax (310) 605-4274 • COVID-19 Online Reporting
***COVID-19 Death Online Reporting Health Professionals Reporting Webpage: www.publichealth.lacounty.gov/clinicians/report

Please Post Revised February 11, 2022 v1



REPORTABLE DISEASES AND CONDITIONS

Title 17, California Code of Regulations (CCR), § 2500

It is the duty of every health care provider, knowing of or in attendance on a case or suspected case of any of the diseases or conditions listed below, to report to the local health officer for the jurisdiction where the patient resides. "Health care provider" encompasses physicians (surgeons, osteopaths, oriental medicine practitioners), veterinarians, podiatrists, physician assistants, registered nurse (nurse practitioners), and as any other person with knowledge of a case or suspected case.

Note: This list is specific to Los Angeles County and differs from state and federal reporting requirements *

Report <u>immediately</u> by telephone (for both confirmed and suspected cases)

NOTE: Monkeypox is an unusual disease which requires immediate report by telephone or Weblink.

OCCURRENCE OF ANY UNUSUAL DISEASE

OUTBREAKS OF ANY DISEASE, including diseases not listed above. Specify if in an institution and/or the open community

- Anthrax, human or animal
- Botulism: infant, foodborne, or wound
- Brucellosis, human
- Chickenpox (Varicella), only hospitalizations, deaths, and outbreaks (≥3 cases, or one case in a high-risk setting)
- Cholera
- COVID-19, hospitalizations (COVID-19 Online Reporting**)

- · Ciguatera Fish Poisoning
- Diphtheria
- Domoic Acid (Amnesic Shellfish) Poisoning
- · Flavivirus infection of undetermined species
- Foodborne Outbreak; 2 or more suspected cases from separate households with same assumed source
- Hemolytic Uremic Syndrome
- Influenza, due to novel strains, human
- Measles (Rubeola)

Reporting***)

Meningococcal Infection

- Middle East Respiratory Syndrome (MERS)
- Novel virus infection with pandemic potential
 Paralytic Shellfish Poisoning
- Plague, human or animal
- · Rabies, human or animal
- Rables, numari or animal
 Scombroid Fish Poisoning
- Shiga Toxin, detected in feces
- Smallpox (Variola)
- Tularemia, human
- Viral Hemorrhagic Fevers, human or animal (e.g., Crimean-Congo, Ebola, Lassa and Marburg viruses)
- Human Immunodeficiency Virus (HIV), acute infection (telephone within 1 working day)
- EX Report by electronic transmission (including FAX or email), telephone or mail within 1 working day from identification

COVID-19, deaths (COVID-19 Death Online

- Babesiosis
- Campylobacteriosis
- Candida auris *
- Chikungunya Virus Infection
- Cryptosporidiosis
- Dengue Virus Infection
- Encephalitis, specify etiology: viral, bacterial, fungal or parasitic
- Escherichia coli, shiga toxin producing (STEC) including E. coli O157
- Foodborne Disease
- Haemophilus influenzae, invasive disease only, all serotypes, less than 5 years of age
- Hantavirus Infection
- Hepatitis A, acute infection

- Listeriosis
- Malaria
- Meningitis, specify etiology: viral, bacterial, fungal, or parasitic
- Paratyphoid Fever
- Pertussis (Whooping Cough)
- Pesticide-Related Illnesses (Health and Safety Code §105200)
- Poliovirus Infection
- Psittacosis
- Q Fever
- · Relapsing Fever
- Salmonellosis, other than Typhoid Fever
- Shigellosis

- Streptococcus pneumoniae: Invasive cases only (sterile body site infections) *
- Streptococcus pyogenes (Group A Streptococcus): Invasive cases only, including necrotizing fasciitis and STSS *
- Syphilis, all stages including congenital
- Trichinosis
- Tuberculosis
- Typhoid Fever, cases and carriers
- Vibrio Infection
- West Nile Virus (WNV) Infection
- Yellow Fever
- Yersiniosis
- Zika Virus Infection

Report by electronic transmission (including FAX or email), telephone or mail within 7 calendar days from identification

- Anaplasmosis
- Brucellosis, animal; except infections due to Brucella canis
- Cancer, including benign and borderline brain tumors (CCR §2593)*
 Carbaneous Resistant Entemperaturiaceae
- Carbapenem-Resistant Enterobacteriaceae (CRE), including Klebsiella sp., E. coli, and Enterobacter sp., in acute care hospitals or skilled nursing facilities ★±
- Chagas Disease ★
- Chancroid
- Coccidioidomycosis
- Creutzfeldt-Jakob Disease and other Transmissible Spongiform Encephalopathies
- Cyclosporiasis
- Cysticercosis or Taeniasis
- *Except basal and squamous skin cancer unless on genital, and carcinoma in-situ and CIN III of the Cervix.

- Disorders Characterized by Lapses of Consciousness (CCR § 2806, § 2810)
- Ehrlichiosis
- Enrichiosi
 Giardiasis
- Gonococcal Infection
- Hepatitis B, specify acute, chronic, or perinatal
- Hepatitis C, specify acute, chronic, or perinatal
- Hepatitis D (Delta), specify acute or chronic
- Hepatitis E, acute infection
- Human Immunodeficiency Virus (HIV) infection, any stage **
- Human Immunodeficiency Virus (HIV) infection, progression to stage 3 (AIDS) **
- Influenza-associated deaths in laboratory confirmed cases, all ages *

- Legionellosis
- Leprosy (Hansen's Disease)
- Leptospirosis
- Lyme Disease
- Mumps
- Myelitis, acute flaccid *
- Nontuberculosis mycobacteria (extrapulmonary) *
- Respiratory Syncytial Virus, only deaths in a patient less than 5 years of age
- Rickettsial Diseases (non-Rocky Mountain Spotted Fever), including Typhus and Typhuslike Illnesses
- Rocky Mountain Spotted Fever
- Rubella (German Measles)
- Rubella Syndrome, Congenital
- Tetanus
- Tularemia, animal

"**Use of FAX for HIV reporting is highly discouraged in order to protect patient confidentiality.

If enrolled, report electronically via the National Healthcare Safety Network (www.cdc.gov/nhsn/index.html).

If not enrolled, use the LAC DPH CRE Case Report Form (publichealth.lacounty.gov/acd/Diseases/EpiForms/CRERepSNF.pdf)

To report a case or outbreak of any disease, contact the Communicable Disease Reporting System
Tel: (888) 397-3993 or (213) 240-7821 • Fax: (888) 397-3778 or (213) 482-5508 • Email: ACDC-MorbidityUnit@ph.lacounty.gov

** COVID-19 Cases Only: COVID19@ph.lacounty.gov • Fax (310) 605-4274 • COVID-19 Online Reporting

***COVID-19 Deaths Only: COVIDdeath@ph.lacounty.gov • COVID-19 Death Online Reporting

Use secure transmission for emailed reports.

Health Professionals Reporting Webpage: www.publichealth.lacounty.gov/clinicians/report

Attachment B IC 104

Sitt Of	E los	LOS ANGELE		SEXUALLY TRAN	ISMITTED DISEASE	COUNTY OF LOS ANGELES
			ONFIDENTIA	AL MORBIDITY R		\$ Public Health
Y Con	DATE OF REPORT (MMDDYY):		REPOR STATU		REPORT DONE BY: (First+Space+Last)	
20000	DIAGNOSING MEDICAL PRACTITIONER	R LAST NAME	-	FIRST NAME		TITLE ABBREVIATION
-						
(1	FACILITY/CLINIC NAME					SUITE/UNIT NO.
Р	FACILITY/CLINIC STREET ADDRESS			<u> </u>		
R						CLINIC STAMP
0	CITY/TOWN					
V	CITYTOWN					
	STATE OFFICE TEL	. (Enter 999-999-99	00 25 00000000	00)		
D. E	STATE OFFICE TELE	(Litter 999-999-99	77 1 1	99)		
R	ZIP CODE OFFICE FAX	1/5-1		00)		
	OFFICE PAY	((Enter 999-999-99	99 85 99999999	99)		
1, 201, 201 1, 201, 201 1, 201, 201, 201	PATIENT'S LAST NAME			FIRST NAME		<u>M.l.</u>
						The state of the s
(2	MEDICAL RECORD NUMBER	AG	SE BIRT	HDAY (MMDDYYYY):	00	CUPATION
	1					***
Р	PATIENT STREET ADDRESS			<u> </u>		APT/UNIT NO.
A						
1	CITY/TOWN			STATE	ZIP CODE	
						HIV cases must be reported to
E	DAY TEL. (Enter 999-999-9999 as 9999	999999)	EVENING T	<u>EL. (Enter 999-999-99</u>	99 as 999999999)	LA County HIV
N]			Epidemiology Program
T	CELL PHONE (Enter 999-999-9999 as 9	999999999)	E-MAIL AD	DRESS		(see section 5)
0.000]			
		<u> </u>	١			
N F	PREGNANT? Unknown No	Yes ▶ If yes, date	of LMP (MMDDYY):		If patient has HIV infection	
1983940538		-	(11111111111111111111111111111111111111			
0					they received HIV partne	LiselActezi — — —
O R		L STATUS (X one):		nat apply):	ETHICITY (X one):	GENDER of SEX PARTNERS
2002/2007	Male Sing	le	White			GENDER of SEX PARTNERS
R M A		le	White Black or A	African American	ETHICITY (X one): Hispanic or Latin	GENDER of SEX PARTNERS (X all that apply):
R M A T	Male Sing Female Marr	le	White Black or A		ETHICITY (X one): Hispanic or Latin	GENDER of SEX PARTNERS (X all that apply): Male Female
R M A T	Male Sing Female Marr Transgender (M to F) Sepa	le ried	White Black or A Native An	African American	ETHICITY (X one): Hispanic or Latin	GENDER of SEX PARTNERS (X all that apply): Male Female Transgender (M to F)
R M A T I O	Male Sing Female Marr Transgender (M to F) Sepa Transgender (F to M) Divo	le ried arated	White Black or A Native An Asian or A	African American nerican or Alaska Nati	ETHICITY (X one): Hispanic or Latin Non-Hispanic/ Non-Latino	GENDER of SEX PARTNERS (X all that apply):
R M A T	Male Sing Female Marr Transgender (M to F) Sepa Transgender (F to M) Divo Unknown Wide	le ried arated arced	White Black or A Native An Asian or A Native Ha	African American nerican or Alaska Nati Asian American awaiian or Pacific Islan	ETHICITY (X one): Hispanic or Latin Non-Hispanic/ Non-Latino	GENDER of SEX PARTNERS (X all that apply):
R M A T I O	Male Sing Female Marr Transgender (M to F) Sepa Transgender (F to M) Divo Unknown Wide	le ried arated rrced owed	White Black or A Native An Asian or A	African American nerican or Alaska Nati Asian American awaiian or Pacific Islan	ETHICITY (X one): Hispanic or Latin Non-Hispanic/ Non-Latino	GENDER of SEX PARTNERS (X all that apply):
R M A T I O	Male Sing Female Marr Transgender (M to F) Sepa Transgender (F to M) Divo Unknown Wide	le ried arated rrced owed	White Black or A Native An Asian or A Native Ha Unknown Other:	African American nerican or Alaska Nati Asian American awalian or Pacific Islan	ETHICITY (X one): Hispanic or Latin Non-Hispanic/ Non-Latino	GENDER of SEX PARTNERS (X all that apply):
R M A T I O N	Male Sing Female Marr Transgender (M to F) Sepa Transgender (F to M) Divo Unknown Wido Other Livin	le ried arated orced owed ng with Partner	White Black or A Native An Asian or A Native Ha Unknown Other:	African American nerican or Alaska Nati Asian American awaiian or Pacific Islan	ETHICITY (X one): Hispanic or Latin Non-Hispanic/ Non-Latino	GENDER of SEX PARTNERS (X all that apply):
R M A T - O Z (M)	Male Sing Female Marr Transgender (M to F) Sepa Transgender (F to M) Divo Unknown Wido Other Livin	le ried arated rrced owed	White Black or A Native An Native Ha Unknown Other: CHLAMYD	African American merican or Alaska Nati Asian American awaiian or Pacific Islar n TA (including	ETHICITY (X one): Hispanic or Latin Non-Hispanic/ Non-Latino	GENDER of SEX PARTNERS (X all that apply):
RMATION (3)D	Male Sing Female Marr Transgender (M to F) Sepa Transgender (F to M) Divo Unknown Wido Other Livin	le ried arated arced bowed ag with Partner	White Black or A Native An Native Ha Unknown Other: CHLAMYD	African American nerican or Alaska Nati Asian American awalian or Pacific Islan	ETHICITY (X one): Hispanic or Latin Non-Hispanic/ Non-Latino	GENDER of SEX PARTNERS (X all that apply):
R M A T - O Z (M)D-1	Male Sing Female Marr Transgender (M to F) Sepa Transgender (F to M) Divo Unknown Wide Other Livin DIAGNOSIS (X one): SITE/SP Asymptomatic Cervix	le ried arated arced bwed ag with Partner	White Black or A Native An Native Ha Unknown Other: CHLAMYD	African American nerican or Alaska Nati Asian American nwaiian or Pacific Islan TA (including	ETHICITY (X one): Hispanic or Latin Non-Hispanic/ Non-Latino	GENDER of SEX PARTNERS (X all that apply):
RMAT-0Z (M)D-A	Male Sing Female Marr Transgender (M to F) Sepa Transgender (F to M) Divo Unknown Wide Other Livin DIAGNOSIS (X one): SITE/SP Asymptomatic Urine Symptomatic Cerviz Uncomplicated Vagin	le ried arated arated orced owed ag with Partner ECIMEN(S) (X all the	White Black or A Native An Asian or A Unknown Other: CHLAMYD at apply): Specimen Colle	African American nerican or Alaska Nati Asian American nwaiian or Pacific Islan TA (including	ETHICITY (X one): Hispanic or Latin Non-Hispanic/ Non-Latino	GENDER of SEX PARTNERS (X all that apply):
RMAH-OZ (M)D-AG	Male Sing Female Marr Transgender (M to F) Sepa Transgender (F to M) Divo Unknown Wide Other Livin DIAGNOSIS (X one): SITE/SP Asymptomatic Urine Symptomatic Cervis	le ried arated arated bywed g with Partner ECIMEN(S) (X all that a	White Black or A Native An Native Ha Unknown Other: CHLAMYD at apply): Specimen Colle Treatment Date	African American nerican or Alaska Nati Asian American nwaiian or Pacific Islan TA (including	ETHICITY (X one): Hispanic or Latin Non-Hispanic/ Non-Latino	GENDER of SEX PARTNERS (X all that apply):
REAH-OZ (M)D-AGZ	Male Sing Female Marr Transgender (M to F) Sepa Transgender (F to M) Divo Unknown Wide Other Livin DIAGNOSIS (X one): SITE/SP. Asymptomatic Urine Symptomatic Cervis uncomplicated Vagin Pelvic Inflammatory Disease	le ried arated browd g with Partner ECIMEN(S) (X all the ara	White Black or A Native An Asian or A Unknown Other: CHLAMYD at apply): Specimen Colle	African American nerican or Alaska Nati Asian American nwaiian or Pacific Islan TA (including	ETHICITY (X one): Hispanic or Latin Non-Hispanic/ Non-Latino	GENDER of SEX PARTNERS (X all that apply):
R M A T I O N D I A G N O	Male Sing Marr Marr Marr Marr Sepater (M to F) Sepater Transgender (M to F) Sepater Marr Marr Marr Marr Marr Marr Marr Ma	le ried arated browed ag with Partner ECIMEN(S) (X ali the a	White Black or A Native An Asian or A Unknown Other: CHLAMYD at apply): Specimen Colle Treatment Date Medication & Dose:	African American merican or Alaska Nati Asian American awaiian or Pacific Islar TA (including ection Date (MMDDY) e (MMDDYY):	ethicity (X one): Hispanic or Latin Non-Hispanic/ Non-Latino PID) ():	GENDER of SEX PARTNERS (X all that apply): Male Female Transgender (M to F) Transgender (F to M) Unknown Other Refused Not Treated
REAH-OZ (M)D-AGZ	Male Sing Female Marr Transgender (M to F) Sepa Transgender (F to M) Divo Unknown Wide Other Livin DIAGNOSIS (X one): SITE/SP. Asymptomatic Urine Symptomatic Cervis uncomplicated Vagin Pelvic Inflammatory Disease	le ried arated browed ag with Partner ECIMEN(S) (X ali the a	White Black or A Native An Native Ha Unknown Other: CHLAMYD at apply): Specimen Colle Treatment Date	African American merican or Alaska Nati Asian American awaiian or Pacific Islar TA (including ection Date (MMDDY) e (MMDDYY):	PID) Number Treated (not including	GENDER of SEX PARTNERS (X all that apply): Male Female Transgender (M to F) Unknown Other Refused Not Treated
R M A T I O N D I A G N O	Male Sing Marr Marr Marr Marr Sepater (M to F) Sepater Transgender (M to F) Sepater Marr Marr Marr Marr Marr Marr Marr Ma	le ried arated browed ag with Partner ECIMEN(S) (X ali the a	White Black or A Native An Asian or A Unknown Other: CHLAMYD at apply): Specimen Colle Treatment Date Medication & Dose: Partner Information:	African American merican or Alaska Nati Asian American awaiian or Pacific Islan IA (including ection Date (MMDDY) e (MMDDYY):	PID) Number Treated (not including PDPT):	GENDER of SEX PARTNERS (X all that apply): Male Female Transgender (M to F) Unknown Other Refused Number Given Patient
R M A T I O N D I A G N O S I S	Male Sing Marr Marr Marr Marr Marr Marr Marr Mar	le ried arated bried growed ag with Partner ECIMEN(S) (X all that a a ara ara	White Black or A Native An Asian or A Unknown Other: CHLAMYD at apply): Specimen Colle Treatment Date Medication & Dose: Partner Information:	African American merican or Alaska Nati Asian American awaiian or Pacific Islar TA (including ection Date (MMDDY) e (MMDDYY):	PID) Number Treated (not including PDPT):	GENDER of SEX PARTNERS (X all that apply): Male Female Transgender (M to F) Unknown Other Refused Not Treated
R M A T I O N D I A G N O S I	Male Sing Marr Marr Marr Marr Marr Marr Marr Mar	le ried arated arated by owed ag with Partner ECIMEN(S) (X all that ara ara ara	White Black or A Native An Asian or A Unknown Other: CHLAMYD at apply): Specimen Colle Treatment Date Medication & Dose: Partner Information: GONORRH) t apply):	African American merican or Alaska Nati Asian American awaiian or Pacific Islan IA (including ection Date (MMDDY) e (MMDDYY):	PID) Number Treated (not including pDPT):	GENDER of SEX PARTNERS (X all that apply): Male Female Transgender (M to F) Unknown Other Refused Number Given Patient Delivered Partner Therapy (PDPT)
R M A T I O N D I A G N O S I S &	Male Sing Marr Marr Marr Marr Marr Marr Marr Mar	le ried arated arated by owed ag with Partner ECIMEN(S) (X all that ara ara ara CIMEN(S) (X all that	White Black or A Native An Asian or A Native Ha Unknown Other: CHLAMYD at apply): Specimen Colle Medication & Dose: Partner Information: GONORRHI t apply): Specimen Colle	African American nerican or Alaska Nati Asian American awaiian or Pacific Islan IA (including ection Date (MMDDY) Number Patners (last 60 days): EA (including) ection Date (MMDDY)	PID) Number Treated (not including pDPT):	GENDER of SEX PARTNERS (X all that apply): Male Female Transgender (M to F) Transgender (F to M) Unknown Other Refused Not Treated Number Given Patient Delivered Partner Therapy (PDPT)
R M A T I O N D I A G N O S I S & T	Male Sing Marr Marr Marr Marr Sepate Marr Marr Marr Marr Marr Marr Marr Mar	le ried arated browd gwith Partner ECIMEN(S) (X all the arated browd CIMEN(S) (X all the CIMEN(S) (X all the CIMEN(S) (X all the	White Black or A Native An Asian or A Unknown Other: CHLAMYD at apply): Specimen Colle Treatment Date Medication & Dose: Partner Information: GONORRH) t apply):	African American nerican or Alaska Nati Asian American awaiian or Pacific Islan IA (including ection Date (MMDDY) Number Patners (last 60 days): EA (including) ection Date (MMDDY)	PID) Number Treated (not including pDPT):	GENDER of SEX PARTNERS (X all that apply): Male Female Transgender (M to F) Unknown Other Refused Number Given Patient Delivered Partner Therapy (PDPT)
R M A T I O N	Male Sing Marr Marr Marr Marr Marr Marr Marr Mar	le ried arated browed g with Partner ECIMEN(S) (X all the arated compared	White Black or A Native An Asian or A Native Ha Unknown Other: CHLAMYD at apply): Specimen Colle Treatment Date Medication & Dose: Partner Information: GONORRHI t apply): Specimen Colle Treatment Date	African American nerican or Alaska Nati Asian American awaiian or Pacific Islan IA (including ection Date (MMDDY) Number Patners (last 60 days): EA (including) ection Date (MMDDY)	PID) Number Treated (not including pDPT):	GENDER of SEX PARTNERS (X all that apply): Male Female Transgender (M to F) Transgender (F to M) Unknown Other Refused Not Treated Number Given Patient Delivered Partner Therapy (PDPT)
R M A T I O N D I A G N O S I S & T R E	Male Sing Marr Marr Marr Marr Separation Marr Marr Marr Marr Marr Marr Marr Mar	le ried arated browed ag with Partner ECIMEN(S) (X all the arated browed ag with Partner CIMEN(S) (X all the arated arated arated arated arated arated	White Black or A Native An Asian or A Native Ha Unknown Other: CHLAMYD at apply): Specimen Colle Medication & Dose: Partner Information: GONORRHI t apply): Specimen Colle	African American nerican or Alaska Nati Asian American awaiian or Pacific Islan IA (including ection Date (MMDDY) Number Patners (last 60 days): EA (including) ection Date (MMDDY)	PID) Number Treated (not including pDPT):	GENDER of SEX PARTNERS (X all that apply): Male Female Transgender (M to F) Transgender (F to M) Unknown Other Refused Not Treated Number Given Patient Delivered Partner Therapy (PDPT)
R M A T I O N	Male Sing Marr Marr Marr Marr Marr Marr Marr Mar	le ried arated browed ag with Partner ECIMEN(S) (X all the arated browed ag with Partner CIMEN(S) (X all the arated arated arated arated arated arated	White Black or A Native An Asian or A Native Ha Unknown Other: CHLAMYD at apply): Specimen Colle Treatment Date Medication & Dose: Partner Information: GONORRHI t apply): Specimen Colle Treatment Date Medications	African American nerican or Alaska Nati Asian American awaiian or Pacific Islan IA (including ection Date (MMDDY) Number Patners (last 60 days): EA (including) ection Date (MMDDY)	PID) Number Treated (not including pDPT):	GENDER of SEX PARTNERS (X all that apply): Male Female Transgender (M to F) Transgender (F to M) Unknown Other Refused Not Treated Number Given Patient Delivered Partner Therapy (PDPT)
R M A T I O N S D I A G N O S I S & T R E A	Male Sing Marr Marr Marr Marr Marr Marr Marr Mar	le ried arated browed ag with Partner ECIMEN(S) (X all the arated browed ag with Partner CIMEN(S) (X all the arated arated arated arated arated arated	White Black or A Native An Asian or A Native Ha Unknown Other: CHLAMYD at apply): Specimen Colle Treatment Date Medication & Dose: Partner Information: GONORRHI t apply): Specimen Colle Treatment Date Medications	African American nerican or Alaska Nati Asian American awaiian or Pacific Islan IA (including ection Date (MMDDY) Number Patners (last 60 days): EA (including) ection Date (MMDDY)	PID) Number Treated (not including pDPT):	GENDER of SEX PARTNERS (X all that apply): Male Female Transgender (M to F) Transgender (F to M) Unknown Other Refused Not Treated Number Given Patient Delivered Partner Therapy (PDPT)
R M A T I O N D I A G N O S I S & T R E A T M E	Male Sing Marr Marr Marr Marr Marr Marr Marr Mar	le ried arated arated by owed ag with Partner ECIMEN(S) (X all that ara ara ara ara ara ara ara ara ara a	White Black or A Native An Asian or A Native Ha Unknown Other: CHLAMYD at apply): Specimen Colle Treatment Date Medication & Dose: Partner Information: GONORRHI t apply): Specimen Colle Treatment Date Medications & Doses:	African American merican or Alaska Nati Asian American awaiian or Pacific Islam IA (including ection Date (MMDDY) e (MMDDYY): Number Pattners (last 60 days): EA (including ection Date (MMDDY) e (MMDDYY):	ETHICITY (X one): Hispanic or Latin Non-Hispanic/ Non-Latino der PID) Number Treated (not including PID) (): Number Treated (not including PID)	GENDER of SEX PARTNERS (X all that apply): Male Female Transgender (M to F) Transgender (F to M) Unknown Other Refused Not Treated Number Given Patient PDPT) Not Treated
RMATION (3)DIAGNOSIS & TREATMEN	Male Sing Marr Marr Marr Marr Marr Marr Marr Mar	le ried arated arated by owed ag with Partner ECIMEN(S) (X all that ara ara ara ara ara ara ara ara ara a	White Black or A Native An Asian or A Native Ha Unknown Other: CHLAMYD at apply): Specimen Colle Treatment Date Medication & Dose: Partner Information: GONORRH t apply): Specimen Colle Treatment Date Medications & Doses:	African American nerican or Alaska Nati Asian American awaiian or Pacific Islan IA (including ection Date (MMDDY) e (MMDDYY): Number Partners Partners (last 60 days): EA (including) ection Date (MMDDY) e (MMDDYY):	PID) Number Treated (not including PDPT): PID) Number Treated (not including PDPT):	GENDER of SEX PARTNERS (X all that apply): Male Female Transgender (M to F) Transgender (F to M) Unknown Other Refused Not Treated Not Treated
RMATION (3) DIAGNOSIS & TREATMENT	Male Sing Marr Marr Marr Marr Marr Marr Marr Mar	le ried arated arated by owed ag with Partner ECIMEN(S) (X all that ara ara ara ara ara ara ara ara ara a	White Black or A Native An Native Ha Unknown Other: CHLAMYD at apply): Specimen Colle Treatment Date Medication & Dose: Partner Information: GONORRHI t apply): Specimen Colle Treatment Date Medications & Dose: Partner Information:	African American nerican or Alaska Nati Asian American awaiian or Pacific Islan IA (including ection Date (MMDDY) e (MMDDYY): Patners (last 60 days): Number Partners (last 60 days):	ETHICITY (X one): Hispanic or Latin Non-Hispanic/ Non-Latino der PID) Number Treated (not including PID) (): Number Treated (not including PID)	GENDER of SEX PARTNERS (X all that apply): Male Female Transgender (M to F) Transgender (F to M) Unknown Other Refused Not Treated Number Given Patient Delivered Partner Therapy Popply (PDPT) Number Given Patient Delivered Partner Therapy Popply (PDPT)

County of Los Angeles • Department of Public Health • TB Control Program TEL (213) 745-0800 FAX (213) 749-0926 Confidential Hospitalized TB Suspect/Case Report (H-803)

**PATIENT:	RECORDED BY:
Last First Mi	Phone () Fax ()
ADDRESS:	Hospital/Clinic where diagnosed
	Medical Record #
PHONE ()	Pt. currently hospitalized? Yes No Adm. Date: / /
BIRTH DATE: / / Sex: Male	emale Treating Physician:
Social Security Number:	Address:
**IF PT. UNDER 18, (PARENT NAME/DOB):	
	Phone ()
Employer/School:	Referred for F/U
OCCUPATION:	Address:
Race:	
Ethnicity: Hispanic Non-Hispanic	Phone ()
Country of Origin: Date of Entry: /_	/ Will MD be continuing TB care? Yes No
Contact Person (name/ph#)	
Date of Diagnosis / / Pulmonary TB	Extra Pulmonary TB
Skin Test Date / Chest X-ray Date: /	Cavitary Non-Cavitary
ResultMM Impression:	
☐ Not done ☐ Unknown	
If Pulmonary, check symptoms	
Cough Hight sweats	nistory of TB Treatment? Yes No
☐ Sputum production ☐ Hemoptysis	where, when treated?
Weight loss(No. of lbs.)	i
If asymptomatic, reason for evaluation	
Other medical conditions relevant to diagnosis:	HIV STATUS DATE: / /
· ·	
	·
BACTERIOLOGY	□ NOT DONE □ REFUSED □ PENDING Patient weight
Pathology Report:	
Talifology Report.	a sychosocial filstory.
Lab Name and Account #:	Allergies:
	8
	MEDICATIONS DOSE START DATE
Specimen Specimen Sme	
Number Collection Date Type AFI	B +/- Isoniazid
	Rifampin
	Ethambutol
	Pyrazinamide
	Rifamate [®]
Additional Comments:	Rifater®
Poto Poported / /	H-802 Rev: 7/06

County of Los Angeles • Department of Public Health • TB Control Program Confidential Hospitalized TB Suspect/Case Report (H-803) Instructions

Reporting of all patients with <u>confirmed</u> or <u>suspected</u> Tuberculosis is mandated by the State Health and Safety Codes (HSC) Division 105, Part 5 and Administrative Codes, Title 17, Chapter 4, Section 2500 and must be done within <u>1 day of diagnosis</u>.

Why do you report?

Because it is required. The Health Department performs many vital functions to ensure public health and safety. These functions include contact investigation, home visits, patient education, patient compliance assessment and directly observed therapy (DOT). Tuberculosis Control staff also will assist in facilitating appropriate discharge planning. HSC section 121361 also mandates that, prior to discharge, all tuberculosis suspects and cases in hospitals and prisons have an individualized, written, discharge plan approved by the Local Health Officer (i.e. TB Controller).

Who must report?

- 1. All health care providers (including administrators of healthcare facilities and clinics) in attendance of a patient suspected to have, or confirmed with, active tuberculosis, must report within 1 working day from the time of identification (California Code: Title 17, Chap. 4, Sec. 2500).
- 2. The director of any clinical lab or designee must report laboratory evidence suggestive of tuberculosis to the Health Department on the same day that the physician who submitted the specimen is notified (California Code: Title 17, Chap. 4, Sec. 2505).

When do you report?

- 1. When the following conditions are present:
 - * signs and symptoms of tuberculosis are present, and/or
 - * the patient has an abnormal CXR consistent with tuberculosis, or
 - the patient is placed on two or more anti-TB drugs
- 2. When bacteriology smears or cultures are positive for acid fast bacilli (AFB)
- 3. When the patient has a positive culture for *M. tuberculosis* complex (i.e., *M. tuberculosis*, *M. bovis*, *M. canettii*, *M. africanum*, *M. microti*).
- 4. When a pathology report is consistent with tuberculosis

How do you report?

The Confidential Hospitalized TB Suspect/Case report (H-803) (on the back of this form) is to be completed in its entirety and submitted to Tuberculosis Control. The Confidential Morbidity Report (ČMR) should not be used for hospitalized patients.

1 BY FAX:

(213) 749-0926

2. BY PHONE:

(213) 745-0800: After hours, leave your name, phone or pager #, patient's name, DOB and

medical record number on voicemail.

3. BY MAIL:

Tuberculosis Control Program 2615 S. Grand Avenue, Room 507 Los Angeles, CA 90007

Reporting tuberculin skin test

Definition of a Positive Tuberculin Skin Test:

≥ 5 mm of induration is considered positive for contacts, suspects and HIV+ or immuno-suppressed individuals of any age.

≥10 mm of induration is considered positive for all other screening subjects of any age.

A positive tuberculin skin test with a normal chest x-ray is not reportable <u>unless</u> the patient is age 3 years or younger. However, health department follow-up may be requested for PPD reactors who also meet one of the following criteria. The reason for referral <u>must</u> be noted on the Remarks section.

- a. HIV infectéd or at risk for HIV infection
- b. Contact to infectious case of tuberculosis
- c. Abnormal chest film consistent with old TB or silicosis
- d. Children 3 years old or under with a positive tuberculin skin test
- e. Documented converters
- f. Medical conditions that increase TB risk:
 - Diabetes mellitus
 - ♦ Prolonged steroid therapy
 - Immunosuppressive therapy
 - End stage renal disease
 - Unexplained rapid weight loss

H-804

County of Los Angeles • Department of Public Health • TB Control Program TEL (213) 745-0800 FAX (213) 749-0926

Confidential Hospitalized TB Suspect / Discharge Care Plan / Approval Request

Patient Name:	Submitted By:
	Phone () Pager ()
	Facility
	Fax # ()
If Pulmonary: Dates of three consecutive negative sm	
<u> </u>	<u></u>
Discharge to: [] Home [] Shelter [] SNF Discharge address and phone:	[] Jail/Prison [] Other
Date patient to be discharged/_/	F/U Appt. Date ///
Physician agreeing to assume TB care	Phono # ()
Health Care Facility	Phone # (<u>)</u>
Address	
Discharge TB medication regimen: (Indicate total daily dose)	Medical complications (specify):
Rifamate [®] (INH+RIF)*pills/day Rifater [®] (INH+RIF+PZA)pills/day	# of days of medication supply
Rifater [®] (INH+RIF+PZA) <u>pills/day</u> INHmg	(Must be sufficient to supply patient until follow up provider appointment).
Rifampin	ргомает арропштетці.
Ethambutol* mg	Page the method them wishes that the U. A. Dir. H.
Pyrazinamide* <u>mg</u> Other <u>mg</u>	Does the patient have risks that indicate Directly Observed Therapy (DOT)?
Side Effects	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
*Current CDC/ATS and Los Angeles County TB Control recommendations for treatment of	[] Mental Impairment [] Homeless
uncomplicated TB for 2 months followed by	[]HIV
INH & RIF for 4 months.	[] Hx of any non-compliant behavior] Substance
[*Contact TB Control if uncertain about risk.
Contact Information/Household composition:	•
Number of people in household?	_
Are there children age 5 years and younger?	. .
Are there individuals immunocompromised? [] Ye	es* []No
DHS Review - Problems Noted	trol use only:
DITO NOVIOW - I TODISHIS NOTEG	Discharge Approved
Action taken before discharge	
, ionali takon balara diamarya	[] Yes [] No
Reviewed by Date reviewed	Date/
Approved by Date reviewed Approved by Date approve	
The Confidential Tuberculosis Suspect Case Report (H-803) form mus	

Revised 7/06

Date Submitted _____ / Faxed by: ___

Los Angeles County • Department of Public Health Tuberculosis Control Program

2615 S. Grand Ave. Room 507 Los Angeles, CA 90007 Phone: 213-745-0800 Fax: 213-749-0926

Confidential Hospitalized TB Suspect/Case Discharge Care Plan / Approval Request (H- 804) Instructions

Discharge of a Suspect or Confirmed Tuberculosis Patient

As of January 1, 1994, State Health and Safety Codes mandate that patients suspected or confirmed with tuberculosis may not be discharged or transferred from a health facility (e.g. hospital) without prior approval of the Local Health Officer (i.e., TB Controller).

To facilitate a timely and appropriate discharge, the provider should submit a written discharge plan to Tuberculosis Control 1 to 2 days prior to the anticipated discharge. Tuberculosis Control will review the discharge plan for approval or denial:

Health Department Response Plan:

Weekly discharge (Non holiday 8:00 am- 5:00 pm): The written discharge plan should be submitted preferably by FAX or mail.

Tuberculosis Control staff will review the discharge plan and notify the provider **within 24 hours** of approval or inform the provider of any additional information/action required or needed for approval prior to discharge.

If a home evaluation is required to determine if the environment is suitable for discharge, health department staff will make a visit.

Holiday and Weekend Discharge: All arrangements for discharge should be made in advance when weekend discharge is anticipated. When unusual circumstances necessitate weekend or holiday discharge, the provider will phone the Los Angeles County Operator at (213) 974-1234 and ask to speak with the Public Health Administrative Officer of the Day (AOD). A response will usually occur within one hour. The process outlined above will be followed. If the discharge cannot be approved, the patient must be held until the next business day until appropriate arrangements can be made (to fulfill State requirements for communicable disease reporting, the Confidential Hospitalized Tuberculosis Suspect/Case Report must be completed and submitted prior to or concurrently with the Confidential Hospitalized Tuberculosis Suspect/Case Discharge Care Plan /Approval Request).

(NOTE: This form is used for discharge care planning only. Call the Tuberculosis Control Program prior to faxing documents to ensure timely processing.)

Rev: 7/06

	PATIENT'S LAST NAME		FIRST NAME M.I.
F			
3.	Primary Onset Date Syphilis (MMDDYY):	ADULT: (LESION SITES [(X all that apply):	SYPHTLTS Genital Rectum Oral Other: Vagina Perirectal
D I A G	Secondary Onset Date Syphilis (MMDDYY):	SYMPTOMS (X all that apply):	Palmar/Plantar Rash Other: Other:
N 0 5 -	Early Latent (<1 year) Late Latent (>1 year) Latent, Unknown Duration	Late Syphilis DESCRIBE Neurosyphilis SYMPTOMS (The diagnosis of neurosyphilis must be acc	companied by a staged diagonsis)
&	Specimen Collection Date (MMDDYY):	Partner information: Numbelicitie	PREGNANT?
T R E A T	RPR or Titer: 1:	Patient Treated: Yes No (III DATE(S) TREATED (MMDDYY)	f yes , give treatment/dose & dates below) Medication & Dose:
M E N	FTA-ABS or Reactive: Yes No		
T	CSF-VDRL Titer: 1:		
	INFANT INFO (Complete sections A & B if this is mother's Cl	DRMATION	AL SYPHILIS (SEPARATE CMRS SHOULD BE SUBMITTED FOR MOTHER & INFANT) MATERNAL INFORMATION (Complete if this is infant's CMR)
(A)	INFANT'S LAST NAME		MOTHER'S LAST NAME
	INFANT'S FIRST NAME		MOTHER'S FIRST NAME
	INFANT'S BIRTH DATE (MMDDYY)	Male Live Birth Female Still Birth	MOTHER'S BIRTH DATE (MMDDYY) Lumbar Puncture Done: Yes No
B	WEIGHT (grams) SYMPTOMS (de	escribe) No symptoms	MOTHER'S SEROLOGY AT DELIVERY Lab Test Date (MMDDYY): MOTHER'S STAGE OF SYPHILIS AT DIAGNOSIS Primary
	GESTATION(wks) Long Bone X-r	rays: Pos. Neg. Not Done	Titer: 1: Early Latent (≤1 year)
	Serum RPR Lab Test Date (MMDDYY):	CSF Laboratory Test Date (MMDDYY):	VORL Late Latent (>1 year) Latent, Unknown Duration
	Reactive → Titer: 1:	VDRL: Non-Reactive Reactive WBC>5/mm³: Yes No	FTA-ABS or Reactive: Yes No Late Syphilis Other DATE(S) TREATED (MMDD&Y) MEDICATION / DOSE
	Not Done Titer 4x > mothers? Yes No	Protein>50mg/dl: Yes No MEDICATION / DOSE	
	DATE INFANT TREATED (MMDDYY):		
		OTHER REPO	DRTABLE STDs \
	DIAGNOSIS TREATED Pelvic	DATE TREATED /	MEDICATION / DOSE
	Inflammatory Yes No Disease (complete if chlamydia & gonorrhea tes	sts are negative or not available. If either test is positive	re, report in chlamydia and/or gonorrhea sections)
	LGV Yes No		
	Chancroid Yes No		
4	FAX BOTH SIDES TO: (213) 749-9602	5 FOR STD CMR FORI	MS: vnload from: http://publichealth.lacounty.gov/std/cmr.htm
S	OR MAIL TO:	or call (213) 741-8000 to	o request forms,
E-N D	STD PROGRAM 2615 S. GRAND AVENUE, RM. 450 LOS ANGELES, CA 90007	O F FOR INFORMATION Visit http://publichealth.i	N AND QUESTIONS ABOUT STD REPORTING: lacounty.gov/std/providers.htm or call (213) 744-3106. NG: lacounty.gov/hiv/hiv/eporting.htm or call (213) 351-8516.

DATE OF REPORT	REPORT New REPORT STATUS Update DONE BY
PATIENT'S LAST NAME	FIRST NAME
PATIENT'S STREET ADDRESS	APT/UNIT NO.
	STATE ZIP CODE
ČÍTY/TOWN	STATE ZP CODE
AREA CODE - DAY TELEPHONE NUMBER	GENDER: PREGNANT: RACE (X all that apply):
(Male Yes Unknown White Black or African American
AREA CODE - EVENING TELEPHONE NUM	Transgender (M to F) OSTRARTIMA
	Transgender (F to M) Unknown or Refused Unknown Refused Native Hawaiian or Pacific Islander Unknown Refused Native Hawaiian or Pacific Islander
Birth Date	AGE: No Unknown Netrused Other:
DOCTOR'S LAST NAME	POCTOR'S FIRST NAME
FACILITY/CLINIC NAME	
FACILITY STREET ADDRESS	SUITE/UNIT NO.
CITY/TOWN	STATE ZIP CODE
AREA CODE TELEPHONE NUMBER	For HIV REPORTING: Call (213) 351-8516 or vi
AREA CODE - TELEPHONE NUMBER	AREA CODE - FAX NUMBER Call (213) 331-6376 U.V.
LABORATORY'S NAME	
EMBORATORT S NAINE	
LABORATORY'S STREET ADDRESS	
CITY/TOWN	STATE ZIP CODE
AREA CODE - TELEPHONE NUMBER	AREA CODE - FAX NUMBER
AREA CODE - TELEPHONE NUMBER	AREA CODE - FAX NUMBER
REFERENCE LABORATORY'S NAME (If specir	len was sent for further testing from original lab to reference lab, reference lab info required in addition to the above information
REFERENCE LABORATORY'S STREET ADDRE	is
	OTATE TID CODE Total AMM DD VVV
CITY/TOWN	STATE ZIP CODE Test Date (MM-DD-YY):
AREA CODE - TELEPHONE NUMBER	AREA CODE - FAX NUMBER Date reported (MM-DD-YY):
	() - (
	CHLAMYDIA
TEST NAME	
TEST RESULT	Chan Call Date (MANA DD) (A)
SPECIMEN TYPE	Spec. Coll. Date (MM-DD-YY):
OI COMMENTE	Test Date (MM-DD-YY);
SPECIMEN SITE:	Specimen ID #:
Urine Vaginal Other	
☐ Cervix ☐ Rectum ☐ Urethra ☐ Nasopharynx	Date reported (MM-DD-YY):
C C (resolvent)	GONORRHEA
TEST NAME	
TEST RESULT	Spor Call Data (MARK DD VVV)
	Spec. Coll. Date (MM-DD-YY):
COTOLATEN TYPE	
SPECIMEN TYPE	Test Date (MM-DD-YY);
SPECIMEN TYPE SPECIMEN SITE:	Test Date (MM-DD-YY):

		ES COUNTY STD PROGRAM S LABORATORY REPORT COUNTY OF LOS ANGELES Public Health
	DATE OF RI	EPORT New REPORT
		TATUS Update DONE BY
(1)	PATIENT'S LAST NAME	FIRST NAME M.I.
M	PATIENT'S STREET ADDRESS	APT/UNIT NO.
	PATIENT 3 STREET ADDRESS	A HOW THE
	CITY/TOWN	STATE ZIP CODE
Р	OT MOVIE	
Α	AREA CODE - DAY TELEPHONE NUMBER	GENDER: PREGNANT: RACE (X all that apply):
Ţ	ALEX GODE TO BAT TELET HOME NOMBEN	GENDER: PREGNANT: RACE (X all that apply): ☐ Male ☐ Yes ☐ Unknown ☐ White
Ė	AREA CODE - EVENING TELEPHONE NUMBER	Female No Black or African American Native American or Alaska Native
N	()) January January	Transgender (M to F) POSTPARTUM: Asian or Asian American
T		Unknown or Refused Tes Unknown Native Hawaiian or Pacific Islander
	Birth Date	AGE: Other: Other:
	DOCTOR'S LAST NAME	DOCTOR'S FIRST NAME M.I.
	FACILITY/CLINIC NAME	
P R		
6	FACILITY STREET ADDRESS	SUITE/UNIT NO.
ΙV		
Ď	CITY/TOWN	STATE ZIP CODE
Ε		For HIV REPORTING: Call (213) 351-8516 or visit
R	AREA CODE - TELEPHONE NUMBER	AREA CODE - FAX NUMBER publichealth.lacounty.gov/hiv/
3	\(\begin{align*} \(\begin{align*} \end{align*} \end{align*} \end{align*} \(\begin{align*} \end{align*} \end{align*} \end{align*} \(\begin{align*} \end{align*} \end{align*} \end{align*} \(\begin{align*} \end{align*} \end{align*} \end{align*} \end{align*} \end{align*} \end{align*} \(\begin{align*} \end{align*} \end{align*} \end{align*} \end{align*} \end{align*} \(\begin{align*} \end{align*} alig	
Z	LABORATORY'S NAME	
L		
A B	LABORATORY'S STREET ADDRESS	
0		
R	CITY/TOWN	STATE ZIP CODE
T	AREA CODE - TELEPHONE NUMBER	AREA CODE - FAX NUMBER
R	() TEELTHORE NORDER	(
(4)	TEST NAME: TEST RESULT:	SYPHILIS SPECIMEN TYPE:
	(X all that apply)	T RIOOD
_	RPR Titer: Reactive - Titer 1: Non-Reac	CSF
E	VDRL Titer: Reactive - Titer 1: Non-Reac	Other (Specify)
S	☐ TP-PA (Serodia): ☐ Reactive ☐ Non-Reactive	
	☐ FTA - ABS: ☐ Reactive ☐ Non-Reactive	Spec. Coll. Date (MM-DD-YY):
E	MHA - TP: Reactive Non-Reactive	
RESU	☐ EIA (IgG/IgM): ☐ Reactive ☐ Non-Reactive	Test Date (MM-DD-YY):
Ĭ	RPR Qualitative: Reactive Non-Reactive	Specimen ID #:
66 E88 24 E86 25 E86		
具	U Other (Specify):	Date reported (MM-DD-YY):
(5)	REFERENCE LABORATORY'S NAME (If specimen was sent for fur	ther testing from original lab to reference lab, reference lab info required in addition to the above information)
`~~		
EFER	REFERENCE LABORATORY'S STREET ADDRESS	
Ŕ		
EZCE	CITY/TOWN	STATE ZIP CODE
Ğ		ADELOGO AND
E	AREA CODE - TELEPHONE NUMBER	AREA CODE - FAX NUMBER
L	TEST NAME.	
LABO	TEST NAME: TEST RESULT: RPR Titer: Reactive - Titer 1: Non-Reac	tive
O R	TP- PA (Serodia): Reactive Non-Reactive	Test Date (MM-DD-YY):
A T	FTA - ABS: Reactive Non-Reactive	Date reported (MM-DD-YY):
T O	MHA - TP: Reactive Non-Reactive	
Ř	Other (Specify):	
E-I-L	FAX TO: (213) 749-9602 REPORTING OR QUESTION: (213) 74	44-3106 DOWNLOAD FROM: HTTP://PUBLICHEALTH.LACOUNTY.GOV/STD/LABS.HTM
Ц.,	- 1. (2.1.) 1 1 Out of one of one of the original of the origina	Updated by 11/04/201